José Baselga joins Verastem's SAB
This article was originally published in Scrip
Verastem, a biopharmaceutical company developing drugs to treat breast and other cancers by targeting cancer stem cells, has elected Dr José Baselga, a renowned breast cancer specialist, to its scientific advisory board. Dr Baselga is currently the Bruce A. Chabner chair and chief of the division of haematology/oncology at Massachusetts General Hospital and associate director of the MGH Cancer Center.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.